Newsroom

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming November 30, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Qfin Holdings, Inc. (“Qfin” or the “Company”) (NASDAQ: QFIN) securities between March 18, 2026 and August 25, 2026, inclusive (the “Class Period”).IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN QFIN HOLDINGS, INC. (QFIN), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONG...

DALLAS--(BUSINESS WIRE)--Celanese to Hold Third Quarter Earnings Conference Call on November 3, 2026...

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, Inc. (ILiAD), una empresa de biotecnología en etapa clínica avanzada enfocada en la prevención y el tratamiento de enfermedades causadas por Bordetella pertussis, anunció el día de hoy la publicación de los resultados de su ensayo clínico de Fase 2b SUPER (Stand Up to Pertussis) en la revista The Lancet Infectious Diseases. Este ensayo aleatorizado, doble ciego y controlado con placebo y comparador activo demostró que BPZE1, una vacuna intra...

DALLAS--(BUSINESS WIRE)--Arcosa, Inc. (NYSE: ACA) (“Arcosa” or the “Company”), a provider of infrastructure-related products and solutions, today announced it will hold quarterly bondholder calls for the benefit of the holders of the Notes, the Trustee, beneficial owners of the Notes, prospective purchasers of the Notes, securities analysts and market making financial institutions to ask questions following the release of its quarterly financial information, beginning with the Quarterly Report...

WESTON, Floride--(BUSINESS WIRE)--ILiAD Biotechnologies, Inc. (ILiAD), une société de biotechnologie au stade clinique avancé spécialisée dans la prévention et le traitement des maladies causées par la bactérie Bordetella pertussis, a annoncé aujourd'hui la publication des résultats de son essai clinique de phase 2b SUPER (Stand Up to Pertussis) dans The Lancet Infectious Diseases. Cet essai randomisé, en double aveugle et contrôlé par placebo et comparateur actif, a démontré que le BPZE1, vacc...

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, Inc. (ILiAD), een biotechnologiebedrijf in een vergevorderd klinisch stadium dat zich richt op de preventie en behandeling van ziekten veroorzaakt door Bordetella pertussis, heeft vandaag de resultaten van zijn fase 2b SUPER (Stand Up to Pertussis) klinische studie gepubliceerd in The Lancet Infectious Diseases. Dit gerandomiseerde, dubbelblinde, met placebo en een actieve vergelijkingsgroep gecontroleerde onderzoek toont aan dat BPZE1, een...

WESTON, Florida--(BUSINESS WIRE)--ILiAD Biotechnologies, Inc. (ILiAD), ein Biotech-Unternehmen im fortgeschrittenen klinischen Stadium, das sich auf die Prävention und Behandlung von durch Bordetella pertussis verursachten Erkrankungen konzentriert, gab heute die Veröffentlichung der Ergebnisse seiner klinischen Phase-2b-Studie SUPER ( S tand U p to Per tussis ) in The Lancet Infectious Diseases bekannt. Diese randomisierte, doppelblinde, placebo- und aktivvergleichskontrollierte Studie zeigte,...

LONDON--(BUSINESS WIRE)--KBRA UK (KBRA) assigns preliminary ratings to five classes of refinancing Notes issued by RRE 11 Loan Management DAC, a cash flow collateralised loan obligation (CLO) backed primarily by a diversified portfolio of Euro-denominated corporate loans. RRE 11 Loan Management DAC is managed by Redding Ridge Asset Management (UK) LLP ("RRAM UK" or the "collateral manager"). The CLO will have a 4.5-year reinvestment period and a 15.0-year legal final. The ratings reflect initia...

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming November 23, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Tigo Energy, Inc. (“Tigo” or the “Company”) (NASDAQ: TYGO) securities between February 24, 2026 and August 4, 2026, inclusive (the “Class Period”).IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN TIGO ENERGY, INC. (TYGO), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOI...

NEW YORK--(BUSINESS WIRE)--BNY Mellon Municipal Bond Infrastructure Fund, Inc. (NYSE: DMB) today announced a distribution of $0.0500 per share of common stock, payable on November 2, 2026 to shareholders of record at the close of business on October 19, 2026. The ex-dividend date is October 19, 2026. The previous distribution announced in September was $0.0500 per share of common stock. The Fund intends to make regular monthly distributions to its common shareholders at a level rate based on it...